PRAX, US74006W2070

H.C. Wainwright keeps USD 1,201 target for Praxis Precision Medicines stock

Published on 10/16/2026 at 00:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

A USD 706.00 target was set for PRAX stock on October 14, 2026. Q2 loss reached USD 83.72 million versus USD 71.13 million a year earlier.

Regulatory dates and analyst targets

H.C. Wainwright kept a USD 1,201.00 target on October 15, 2026.
Praxis reported USD 96.9 million in operating expenses for the second quarter of 2026.
The relutrigine PDUFA decision is scheduled for December 27, 2026.

PRAX, US74006W2070, Illustration mit AI erstellt.

Praxis Precision Medicines (ISIN US74006W2070) received a USD 1,201.00 price target from H.C. Wainwright on October 15, 2026, according to Markets Insider. The latest analyst actions keep attention on Praxis as two late-stage drug applications approach regulatory decisions.

Analysts raise the valuation bar

UBS initiated coverage with a Buy rating and a USD 706.00 target on October 14, 2026, as Markets Insider reported. The target is materially above the USD 248.24 Nasdaq quote from October 15, 2026, while the company remains in a pre-commercial stage.

Praxis reported a GAAP net loss of USD 83.72 million for the second quarter of 2026, compared with USD 71.13 million a year earlier. The result came alongside preparations for potential launches of ulixacaltamide and relutrigine.

Three milestones shape the story

On August 6, 2026, Praxis reported adjusted earnings per share of minus USD 2.87 for the second quarter, versus a consensus loss of USD 3.67, according to Benzinga. On October 2, 2026, the company announced inducement grants covering 3,478 shares for 14 new employees in a release distributed through GlobeNewswire. H.C. Wainwright then maintained its USD 1,201.00 target on October 15, 2026.

What does USD 96.9 million mean for launches?

Operating expenses reached USD 96.9 million in the second quarter of 2026, including USD 69.4 million for research and development and USD 27.5 million for general and administrative costs. Operating cash use was USD 78.0 million, compared with USD 55.0 million in the second quarter of 2025, while cash, cash equivalents and marketable securities totaled USD 1.4 billion at quarter-end.

Two regulatory dates remain

The FDA target action date for relutrigine is December 27, 2026, while the PDUFA decision for ulixacaltamide is scheduled for January 29, 2027, as reported by Markets Insider. Those dates provide the clearest near-term timetable for the company.

Market value and pipeline timing

Praxis had a market capitalization of USD 6.9 billion on October 15, 2026. Its 52-week range was USD 154.45 to USD 392.70, placing the regulatory calendar alongside a wide valuation range for a biotechnology company approaching potential commercialization.